LONDON (AP) — AstraZeneca has outlined plans to grow annual sales to more than $45 billion by 2023 as an independent company, days after the drugmaker rejected a takeover bid by rival Pfizer.
In an update to shareholders, AstraZeneca said investors would share the benefits of a "strong and consistent revenue growth" projected for 2017-2023.
The U.K.-based company on Friday spurned Pfizer's third acquisition proposal, this time for about $106 billion. AstraZeneca PLC, the No. 8 drugmaker, called that inadequate and said the potentially lucrative "pipeline" of new drugs it is developing would be disrupted by a takeover.
AstraZeneca's revenues last year were $25.7 billion, down 6 percent on the previous year, but the company said Tuesday that under its new management and strategy it is now "repositioned for a return to growth."
Original headline: AstraZeneca fends off Pfizer with new growth plan
Most Popular Stories
- Pandora Tumbles in Late Trading
- Sporty Ford Fiesta Fires on All 3 Cylinders
- Stop-Start Engines Save Gas, Reduce Emissions
- World Tensions Don't Curb Enthusiasm for Stocks
- Russia Fears Lasting Damage From Ukraine Crisis
- Visa, Amazon Results Drag Down the Street
- U.K. Economy Surpasses Pre-Crisis Peak
- Ohio State Band Chief Fired After Probe
- Hispanic Leader Goes the Extra Mile
- Shia LaBeouf Plea Deal, Alcoholism Treatment